BRCA1 is a component of the RNA polymerase II holoenzyme.

The familial breast-ovarian tumor suppressor gene product BRCA1 was found to be a component of the RNA polymerase II holoenzyme by several criteria. BRCA1 was found to copurify with the holoenzyme over multiple chromatographic steps. Other tested transcription activators that could potentially contact the holoenzyme were not stably associated with the holoenzyme as determined by copurification. Antibody specific for the holoenzyme component hSRB7 specifically purifies BRCA1. Immunopurification of BRCA1 complexes also specifically purifies transcriptionally active RNA polymerase II and transcription factors TFIIF, TFIIE, and TFIIH. Moreover, a BRCA1 domain, which is deleted in about 90% of clinically relevant mutations, participates in binding to the holoenzyme complex in cells. These data are consistent with recent data identifying transcription activation domains in the BRCA1 protein and link the BRCA1 tumor suppressor protein with the transcription process as a holoenzyme-bound protein.

[1]  R. Young,et al.  General requirement for RNA polymerase II holoenzymes in vivo. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[2]  R. Roeder,et al.  Cooperative interaction of an initiator-binding transcription initiation factor and the helix–loop–helix activator USF , 1991, Nature.

[3]  A. Barberis,et al.  Gene activation by recruitment of the RNA polymerase II holoenzyme. , 1996, Genes & development.

[4]  E. Lees,et al.  Cyclin C/CDK8 is a novel CTD kinase associated with RNA polymerase II. , 1996, Oncogene.

[5]  M. Gerritsen,et al.  CREB-binding protein/p300 are transcriptional coactivators of p65. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Young,et al.  RNA Polymerase II Holoenzyme Contains SWI/SNF Regulators Involved in Chromatin Remodeling , 1996, Cell.

[7]  Pamela Reinagel,et al.  Contact with a component of the polymerase II holoenzyme suffices for gene activation , 1995, Cell.

[8]  Yonghong Xiao,et al.  Association of BRCA1 with Rad51 in Mitotic and Meiotic Cells , 1997, Cell.

[9]  M. Skolnick,et al.  BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.

[10]  U. Schibler,et al.  A mammalian RNA polymerase II holoenzyme containing all components required for promoter-specific transcription initiation , 1995, Cell.

[11]  Danny Reinberg,et al.  A human RNA polymerase II complex associated with SRB and DNA-repair proteins , 1996, Nature.

[12]  J. Direnzo,et al.  p300 is a component of an estrogen receptor coactivator complex. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  H. Hanafusa,et al.  Evidence for a transcriptional activation function of BRCA1 C-terminal region. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Kieff,et al.  Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa , 1995, Journal of virology.

[15]  M. King,et al.  Inherited breast and ovarian cancer. , 1995, Human molecular genetics.

[16]  I. Verma,et al.  Transcriptional activation by BRCA1 , 1996, Nature.

[17]  Richard A. Young,et al.  An RNA polymerase II holoenzyme responsive to activators , 1994, Nature.

[18]  S. Bhattacharya,et al.  Cooperation of Stat2 and p300/CBP in signalling induced by interferon-α , 1996, Nature.

[19]  Thomas Shenk,et al.  YY1 is an initiator sequence-binding protein that directs and activates transcription in vitro , 1991, Nature.

[20]  E. Nigg,et al.  Identification of human cyclin-dependent kinase 8, a putative protein kinase partner for cyclin C. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  Yang Li,et al.  A multiprotein mediator of transcriptional activation and its interaction with the C-terminal repeat domain of RNA polymerase II , 1994, Cell.

[22]  S. Neuhausen,et al.  Loss of heterozygosity in familial tumors from three BRCA1-linked kindreds. , 1994, Cancer Research.

[23]  S. F. Anderson,et al.  A mammalian SRB protein associated with an RNA polymerase II holoenzyme , 1996, Nature.

[24]  R. Young,et al.  A kinase–cyclin pair in the RNA polymerase II holoenzyme , 1995, Nature.

[25]  E. Moran,et al.  Relief of YY1 transcriptional repression by adenovirus E1A is mediated by E1A-associated protein p300. , 1995, Genes & development.

[26]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[27]  C. Osborne,et al.  Location of BRCA1 in Human Breast and Ovarian Cancer Cells , 1996, Science.

[28]  S. F. Anderson,et al.  Analysis of a cAMP-responsive activator reveals a two-component mechanism for transcriptional induction via signal-dependent factors. , 1997, Genes & development.

[29]  D. Easton,et al.  Allele losses in the region 17q12–21 in familial breast and ovarian cancer involve the wild–type chromosome , 1992, Nature Genetics.

[30]  P. Sharp,et al.  In vitro transcription: whole-cell extract. , 1983, Methods in enzymology.

[31]  N. Thompson,et al.  Purification of eukaryotic RNA polymerase II by immunoaffinity chromatography. Elution of active enzyme with protein stabilizing agents from a polyol-responsive monoclonal antibody. , 1990, The Journal of biological chemistry.

[32]  M. Montminy,et al.  Role of CBP/P300 in nuclear receptor signalling , 1996, Nature.